Atricure reports first quarter 2025 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced first quarter 2025 financial results. “our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said michael carrel, president and chief executive officer at atricure. “as.
ATRC Ratings Summary
ATRC Quant Ranking